ER2001 injection

DRUG2 trials

Sponsors

ExoRNA Bioscience

Conditions

Huntington Disease

Early Phase 1

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

CompletedNCT06024265

ExoRNA BioscienceHuntington Disease

Start: 2023-04-04End: 2025-09-04Updated: 2025-12-19

The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.

CompletedNCT07344519

ExoRNA BioscienceHuntington Disease

Start: 2024-06-25End: 2026-01-31Updated: 2026-05-22